What is an expected outcome of administering VZIG to a newborn?

Administering Varicella Zoster Immune Globulin (VZIG) to a newborn is specifically intended to prevent varicella (chickenpox) infection in infants who have been exposed to the varicella virus, particularly in cases where the mother is not immune. VZIG provides passive immunity by supplying the newborn with antibodies that help protect against the varicella virus during a critical period when the infant's own immune system is still developing. This protective effect is essential because neonates are at a higher risk of severe disease if they contract varicella.

The other choices don't accurately describe the outcomes associated with VZIG administration. For example, VZIG does not provide immediate immunity against all infections, nor does it enhance immune responses to minor illnesses like common colds or confer long-term immunity against various viruses. It specifically targets the varicella virus, thus emphasizing the importance of VZIG in preventing varicella infection in newborns exposed to the virus.